133 related articles for article (PubMed ID: 23628552)
1. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.
van der Helm LH; Veeger NJ; Kooy Mv; Beeker A; de Weerdt O; de Groot M; Alhan C; Hoogendoorn M; Laterveer L; van de Loosdrecht AA; Koedam J; Vellenga E; Huls G
Leuk Res; 2013 Aug; 37(8):877-82. PubMed ID: 23628552
[TBL] [Abstract][Full Text] [Related]
2. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Thépot S; Itzykson R; Seegers V; Recher C; Raffoux E; Quesnel B; Delaunay J; Cluzeau T; Marfaing Koka A; Stamatoullas A; Chaury MP; Dartigeas C; Cheze S; Banos A; Morel P; Plantier I; Taksin AL; Marolleau JP; Pautas C; Thomas X; Isnard F; Beve B; Chait Y; Guerci A; Vey N; Dreyfus F; Ades L; Ifrah N; Dombret H; Fenaux P; Gardin C;
Am J Hematol; 2014 Apr; 89(4):410-6. PubMed ID: 24375487
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
[TBL] [Abstract][Full Text] [Related]
4. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute myelogenous leukemia with outpatient azacitidine.
Sudan N; Rossetti JM; Shadduck RK; Latsko J; Lech JA; Kaplan RB; Kennedy M; Gryn JF; Faroun Y; Lister J
Cancer; 2006 Oct; 107(8):1839-43. PubMed ID: 16967444
[TBL] [Abstract][Full Text] [Related]
6. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
Radujkovic A; Dietrich S; Bochtler T; Krämer A; Schöning T; Ho AD; Dreger P; Luft T
Eur J Haematol; 2014 Aug; 93(2):112-7. PubMed ID: 24628527
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
[TBL] [Abstract][Full Text] [Related]
9. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program.
Maurillo L; Venditti A; Spagnoli A; Gaidano G; Ferrero D; Oliva E; Lunghi M; D'Arco AM; Levis A; Pastore D; Di Renzo N; Santagostino A; Pavone V; Buccisano F; Musto P
Cancer; 2012 Feb; 118(4):1014-22. PubMed ID: 21761399
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
[TBL] [Abstract][Full Text] [Related]
12. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.
Tombak A; Uçar MA; Akdeniz A; Tiftik EN; Gören Şahin D; Akay OM; Yıldırım M; Nevruz O; Kis C; Gürkan E; Solmaz ŞM; Özcan MA; Yıldırım R; Berber İ; Erkurt MA; Fıratlı Tuğlular T; Tarkun P; Yavaşoğlu İ; Doğu MH; Sarı İ; Merter M; Özcan M; Yıldızhan E; Kaynar L; Mehtap Ö; Uysal A; Şahin F; Salim O; Sungur MA
Turk J Haematol; 2016 Dec; 33(4):273-280. PubMed ID: 27095141
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.
Al-Ali HK; Jaekel N; Junghanss C; Maschmeyer G; Krahl R; Cross M; Hoppe G; Niederwieser D
Leuk Lymphoma; 2012 Jan; 53(1):110-7. PubMed ID: 21767242
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
15. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer L; Burgstaller S; Girschikofsky M; Linkesch W; Stauder R; Pfeilstocker M; Schreder M; Tinchon C; Sliwa T; Lang A; Sperr WR; Krippl P; Geissler D; Voskova D; Schlick K; Thaler J; Machherndl-Spandl S; Theiler G; Eckmüllner O; Greil R
Ann Hematol; 2014 Nov; 93(11):1825-38. PubMed ID: 24951123
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
Ramos F; Thépot S; Pleyer L; Maurillo L; Itzykson R; Bargay J; Stauder R; Venditti A; Seegers V; Martínez-Robles V; Burgstaller S; Récher C; Debén G; Gaidano G; Gardin C; Musto P; Greil R; Sánchez-Guijo F; Fenaux P;
Leuk Res; 2015 Mar; 39(3):296-306. PubMed ID: 25601157
[TBL] [Abstract][Full Text] [Related]
17. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
Amin HM; Yang Y; Shen Y; Estey EH; Giles FJ; Pierce SA; Kantarjian HM; O'Brien SM; Jilani I; Albitar M
Leukemia; 2005 Sep; 19(9):1567-72. PubMed ID: 16049515
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
Gemuenden C; Benz R; Senn O; Goede JS; Manz MG; Gerber B
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
[TBL] [Abstract][Full Text] [Related]
19. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
Haferlach T; Kern W; Schoch C; Schnittger S; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
Haematologica; 2004 Apr; 89(4):408-18. PubMed ID: 15075074
[TBL] [Abstract][Full Text] [Related]
20. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
